Altered expression of ETV1 and its contribution to tumorigenic phenotypes in gastrointestinal stromal tumors

Zhang,Yan; Gu,Meng-Li; Zhou,Xin-Xin; Ma,Han; Yao,Hang-Ping; Ji,Feng

doi:10.3892/or.2014.3281

Altered expression of ETV1 and its contribution to tumorigenic phenotypes in gastrointestinal stromal tumors

Authors:
- Yan Zhang
- Meng-Li Gu
- Xin-Xin Zhou
- Han Ma
- Hang-Ping Yao
- Feng Ji
View Affiliations

Affiliations: Department of Gastroenterology, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, Zhejiang 310003, P.R. China, Viral Oncogenesis Section of the State Key Laboratory for Diagnosis and Treatment of Infectious Diseases, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, Zhejiang 310003, P.R. China
Published online on: June 23, 2014 https://doi.org/10.3892/or.2014.3281
Pages: 927-934

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Gastrointestinal stromal tumor (GIST) is the most common mesenchymal neoplasm of the gastrointestinal tract. ETV1 is a unique transcription factor specific to GIST that has been reported to date. The present study aimed to determine aberrant ETV1 expression and its contribution to tumorigenesis in GISTs. Altered expression levels of ETV1 and its relevant signaling pathways were assessed using western blotting and quantitative real-time PCR in 72 paired patient tissue samples. In addition, immunochemistry was performed on 156 GISTs using tissue microarray to analyze the correlation between ETV1 and clinical parameters. The results revealed that ETV1 was highly expressed in the GISTs at both the transcription and protein levels. Immunochemical analysis revealed that increased expression of ETV1 was correlated with KIT in the 156 patients. In addition, the frequency of ETV1 positivity was higher when compared with KIT [50.0% (9/18) vs 38.9% (7/18)] particularly in high-risk GISTs. Analysis of western blotting data showed that total protein isoforms of Raf, MEK and ERK were similar in the GIST tissues as well as in the uninvolved normal tissues. In contrast, the level of phospho-Raf, phospho-MEK and phospho‑ERK were decreased in the tumor group. Moreover, enhanced signaling molecules such as Bcl-2 and Dvl2/GSK-3β/β-catenin/Smad2 were detected, showing a significant difference in comparison with the uninvolved normal cases. We conclude that ETV1, a member of the ETS family, is upregulated in GISTs, and its signaling is integrated into a cellular signaling network for resistance to apoptosis, tumor cell invasion and survival.

View Figures

View References

1	Corless CL, Barnett CM and Heinrich MC: Gastrointestinal stromal tumours: origin and molecular oncology. Nat Rev Cancer. 11:865–878. 2011.PubMed/NCBI
2	Rubin BP, Heinrich MC and Corless CL: Gastrointestinal stromal tumour. Lancet. 369:1731–1741. 2007. View Article : Google Scholar : PubMed/NCBI
3	Downs-Kelly E and Rubin BP: Gastrointestinal stromal tumors: molecular mechanisms and targeted therapies. Patholog Res Int. 2011:7085962011.PubMed/NCBI
4	Blay JY: A decade of tyrosine kinase inhibitor therapy: historical and current perspectives on targeted therapy for GIST. Cancer Treat Rev. 37:373–384. 2011. View Article : Google Scholar : PubMed/NCBI
5	Rubin BP: Bioinformatic mining of gene expression datasets identifies ETV1 as a critical regulator of oncogenesis in gastrointestinal stromal tumors. Cancer Cell. 18:407–408. 2010. View Article : Google Scholar : PubMed/NCBI
6	Chen Y, Zou H, Yang LY, Li Y, Wang L, Hao Y and Yang JL: ER81-shRNA inhibits growth of triple-negative human breast cancer cell line MDA-MB-231 in vivo and in vitro. Asian Pac J Cancer Prev. 13:2385–2392. 2012. View Article : Google Scholar : PubMed/NCBI
7	Shin S, Bosc DG, Ingle JN, Spelsberg TC and Janknecht R: Rcl is a novel ETV1/ER81 target gene upregulated in breast tumors. J Cell Biochem. 105:866–874. 2008. View Article : Google Scholar : PubMed/NCBI
8	Baena E, Shao Z, Linn DE, et al: ETV1 directs androgen metabolism and confers aggressive prostate cancer in targeted mice and patients. Genes Dev. 27:683–698. 2013. View Article : Google Scholar
9	Hollenhorst PC, Ferris MW, Hull MA, Chae H, Kim S and Graves BJ: Oncogenic ETS proteins mimic activated RAS/MAPK signaling in prostate cells. Genes Dev. 25:2147–2157. 2011. View Article : Google Scholar : PubMed/NCBI
10	Jané-Valbuena J, Widlund HR, Perner S, et al: An oncogenic role for ETV1 in melanoma. Cancer Res. 70:2075–2084. 2010.
11	Oh S, Shin S and Janknecht R: ETV1, 4 and 5: an oncogenic subfamily of ETS transcription factors. Biochim Biophys Acta. 1826:1–12. 2012.PubMed/NCBI
12	Chi P, Chen Y, Zhang L, et al: ETV1 is a lineage survival factor that cooperates with KIT in gastrointestinal stromal tumours. Nature. 467:849–853. 2010. View Article : Google Scholar : PubMed/NCBI
13	Duensing A, Medeiros F, McConarty B, et al: Mechanisms of oncogenic KIT signal transduction in primary gastrointestinal stromal tumors (GISTs). Oncogene. 23:3999–4006. 2004. View Article : Google Scholar : PubMed/NCBI
14	Duensing S and Duensing A: Targeted therapies of gastrointestinal stromal tumors (GIST) - the next frontiers. Biochem Pharmacol. 80:575–583. 2010. View Article : Google Scholar : PubMed/NCBI
15	Nelson WJ and Nusse R: Convergence of Wnt, β-catenin, and cadherin pathways. Science. 303:1483–1487. 2004.
16	Pal M, Koul S and Koul HK: The transcription factor sterile alpha motif (SAM) pointed domain-containing ETS transcription factor (SPDEF) is required for E-cadherin expression in prostate cancer cells. J Biol Chem. 288:12222–12231. 2013. View Article : Google Scholar : PubMed/NCBI
17	Heinrich MC and Corless CL: Cancer: oncogenes in context. Nature. 467:796–797. 2010. View Article : Google Scholar : PubMed/NCBI
18	Kim EK and Choi EJ: Pathological roles of MAPK signaling pathways in human diseases. Biochim Biophys Acta. 1802:396–405. 2010. View Article : Google Scholar : PubMed/NCBI
19	Schoppmann SF, Beer A, Nirtl N, Ba-Ssalamah A, Brodowicz T, Streubel B and Birner P: Downregulation of phosphatidylethanolamine binding protein 1 associates with clinical risk factors in gastrointestinal stromal tumors, but not with activation of the RAF-1-MEK-ETV1 pathway. Cancer Lett. 335:26–30. 2013. View Article : Google Scholar : PubMed/NCBI
20	Gulmann C, Sheehan KM, Conroy RM, et al: Quantitative cell signalling analysis reveals down-regulation of MAPK pathway activation in colorectal cancer. J Pathol. 218:514–519. 2009. View Article : Google Scholar : PubMed/NCBI
21	Braig M, Lee S, Loddenkemper C, et al: Oncogene-induced senescence as an initial barrier in lymphoma development. Nature. 436:660–665. 2005. View Article : Google Scholar : PubMed/NCBI
22	Wu PK, Hong SK, Veeranki S, Karkhanis M, Starenki D, Plaza JA and Park JI: A mortalin/HSPA9-mediated switch in tumor-suppressive signaling of Raf/MEK/extracellular signal-regulated kinase. Mol Cell Biol. 33:4051–4067. 2013. View Article : Google Scholar : PubMed/NCBI
23	Mooi WJ and Peeper DS: Oncogene-induced cell senescence - halting on the road to cancer. N Engl J Med. 355:1037–1046. 2006. View Article : Google Scholar : PubMed/NCBI
24	Klonisch T, Wiechec E, Hombach-Klonisch S, Ande SR, Wesselborg S, Schulze-Osthoff K and Los M: Cancer stem cell markers in common cancers - therapeutic implications. Trends Mol Med. 14:450–460. 2008. View Article : Google Scholar : PubMed/NCBI
25	Ghavami S, Hashemi M, Ande SR, et al: Apoptosis and cancer: mutations within caspase genes. J Med Genet. 46:497–510. 2009. View Article : Google Scholar : PubMed/NCBI
26	Liu J, Cui H, Peng X, et al: Dietary high fluorine induces apoptosis and alters Bcl-2, Bax, and caspase-3 protein expression in the cecal tonsil lymphocytes of broilers. Biol Trace Elem Res. 52:25–30. 2013. View Article : Google Scholar : PubMed/NCBI
27	Steinert DM, Oyarzo M, Wang X, et al: Expression of Bcl-2 in gastrointestinal stromal tumors: correlation with progression-free survival in 81 patients treated with imatinib mesylate. Cancer. 106:1617–1623. 2006. View Article : Google Scholar : PubMed/NCBI
28	Wang Q and Kou YW: Study of the expressions of p53 and bcl-2 genes, the telomerase activity and apoptosis in GIST patients. World J Gastroenterol. 13:2626–2628. 2007. View Article : Google Scholar : PubMed/NCBI
29	Nogueira V, Park Y, Chen CC, et al: Akt determines replicative senescence and oxidative or oncogenic premature senescence and sensitizes cells to oxidative apoptosis. Cancer Cell. 14:458–470. 2008. View Article : Google Scholar : PubMed/NCBI
30	Seki E, Brenner DA and Karin M: A liver full of JNK: signaling in regulation of cell function and disease pathogenesis, and clinical approaches. Gastroenterology. 143:307–320. 2012. View Article : Google Scholar : PubMed/NCBI
31	Corazza N, Jakob S, Schaer C, et al: TRAIL receptor-mediated JNK activation and Bim phosphorylation critically regulate Fas-mediated liver damage and lethality. J Clin Invest. 116:2493–2499. 2006. View Article : Google Scholar : PubMed/NCBI
32	De Craene B and Berx G: Regulatory networks defining EMT during cancer initiation and progression. Nat Rev Cancer. 13:97–110. 2013.PubMed/NCBI
33	Birner P, Beer A, Vinatzer U, et al: MAPKAP kinase 2 overexpression influences prognosis in gastrointestinal stromal tumors and associates with copy number variations on chromosome 1 and expression of p38 MAP kinase and ETV1. Clin Cancer Res. 18:1879–1887. 2012. View Article : Google Scholar : PubMed/NCBI
34	Kubota D, Yoshida A, Tsuda H, et al: Gene expression network analysis of ETV1 reveals KCTD10 as a novel prognostic biomarker in gastrointestinal stromal tumor. PLoS One. 8:e738962013. View Article : Google Scholar : PubMed/NCBI